Recent advances on patents in poly(ethylene glycol)-based drug delivery

Recent Patents on Drug Delivery and Formulation

Volumn 2, Issue 2, 2008, Pages 189-195

  Bonora, Gian M ^a   Drioli, Sara ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Biomaterials; Conjugates; Drug; Drug delivery; Oligonucleotides; Peptide; Poly(ethylene glycol); Proteins

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ASPARAGINASE MACROGOL; BIOPOLYMER; BIPHALIN; CAMPTOTHECIN; CYTARABINE; DRUG CARRIER; ENKEPHALIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN GROWTH HORMONE; INTERFERON; LIPOSOME; MACROGOL; MACROGOL 2000; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; OPIATE PEPTIDE; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEPTIDE; POLYLYSINE; POLYMER; PROTEIN DERIVATIVE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SOMATOSTATIN DERIVATIVE; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; BIODEGRADABILITY; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG PENETRATION; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSPORT; GROWTH DISORDER; HUMAN; HYDROPHOBICITY; KIDNEY CARCINOMA; LIPOPHILICITY; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; OLIGONUCLEOTIDES; PATENTS AS TOPIC; PEPTIDES; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; PROTEINS;

EID: 55849108137     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221108784534063     Document Type: Review

References (55)

1. Harris AJM. Poly(ethylene Glycol Chemistry. Biotechnical and Biomedical Application, Topics in Applied Chemistry. Plenum Press, New York. 1992; B. Harris JM Zalipsky S. (Eds), Poly(ethylene glycol). Chemistry and Biological Applications. ACS Symposium Series 680, ACS, Washington, DC, 1997.
2. Dickerson JT, Reed NN, Janda KD. Soluble polymers as scaffolds for recoverable catalysts and reagents. Chem Rev 2002; 102: 3325-3344.
3. Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002; 54: 457-458.
4. Guiotto A, Pozzobon M, Sanavio C, Schiavon O, Orsolini P, Veronese FM. An improved procedure for the synthesis of branched polyethylene glycols (PEGs) with the reporter dipeptide met-βala for protein conjugation. Bioorg Med Chem Lett 2002; 12: 177-180.
5. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54: 459-476.
6. Motzer RJ, Rakhit A, Thompson J, et al. Phase II trial of branched PEGinterferon-α 2a (40 kDa) for patients with advanced renal cell carcinoma. Annals Oncology 2002; 13: 1799-1805.
7. Matou EJ, Pou ková P, Sou EJ, Kvor J. PEG chains increase aspermatogenic and antitumour activity of RNase A and BS-RNase enzymes. J. of Controlled Release 2002; 82: 29-37.
8. Li W, Wang Y, Zhu X, Li M, Su. Z. Preparation and characterization of PEGylated adducts of recombinant human tumour necrosis factor alpha from Escherichia coli. J Biotechnol 2002; 92: 251-258.
9. Morpurgo M, Monfardini C, Hofland LJ, et al. Selective alkylation and acylation of alpha and epsilon amino groups with PEG in a somatostatine analogue: tailored chemistry for optimized bioconjugates. Bioconjugate Chem 2002; 13: 1238-1243.
10. Desjarlais, J.R., Zalevsky, J.: WO04089421A2 (2004).
11. Chavez, M.D., Orpiszewsky, J.: WO05042563A2 (2005).
12. El Tayar, N., Roberts, M.J., Harris, M., Sawlivich, W.: EP1421956B1 (2007).
13. Ramakrishnan, V.: WO06028634A2 (2006).
14. Hsei, V., Koumenis, I., Leong, S., Shahrokh, Z., Zapata, G.: US20077214776 (2007).
15. Finn, R.E., Soegel, N.R.: WO06024953A2 (2006).
16. Novick, D., Dinarello, C., Rubinstein, M., Kim, S.-H., Fantuzzi, G., Reznikov, L., Schwartsburd, B.: US20070081975A1 (2007).
17. Zhang G, Leibowitz MJ, Sinko PJ, Stein S. Multiple-peptide conjugates for binding beta-amyloid plaques of Alzaheimer's disease. Bioconjugate Chem 2003; 14: 86-92.
18. Vhelan, J., Pan, C.: WO05123109A2 (2005).
19. Di Marchi, R.D., Smiley, D.L.: WO07056362A2 (2007).
20. Bentley, M., Roberts, M.: EP1221975B1 (2007).
21. Atsushi, M., Takagi, A., Saito, K., Yamashita, N., Yoshioka, J.: US20077169892 (2007).
22. Bonora GM. Polymer-conjugated bioactive oligonucleotides. J. of Bioactive and Compatible Polymers 2002; 17: 375-390.
23. Cogoi S, Ballico M, Bonora GM, Xodo L. Inhibition of Ki-ras gene by a triple helix-forming oligonucleotide conjugated to high-molecular weight polyethylene glycol in carcinoma pancreatic cells. Cancer Gene Therapy 2004; 11: 465-476.
24. Zhao O, Peng P, Longley C, et al. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy. J Controll Release 2007; 119: 143-152.
25. McSwiggen, J., Guerciolini, R., Pavco, P.: WO07067981A2 (2007).
26. Schiavon O, Pasut G, Moro S, Orsolini P,Guiotto A. Veronese FM. PEG-Ara-C conjugates for controlled release. Eur. J. Med. Chem. 2004; 39: 123-133.
27. Fleming AB, Haverstick K, Saltzman WM. in vitro Citotoxicity and in vivo distribution after direct delivery of PEG-Camptothecin conjugates to the rat brain. Bioconjugate Chem 2004; 15: 1364-1375.
28. Greenwald RB, Pendri A, Bolikal D. Highly water soluble taxol derivatives. 7-Polyehtylene glycol carbamates and carbonates. J Org Chem 1995; 60: 331-336.
29. Pechar M, Braunova A, Ulbrich K, Jelinkova M, Rihova B. Poly(ethylene glycol)-Doxorubicin conjugates with pH-controleld activation. J Bioact Compat Polym 2005; 20: 319-341.
30. Dequan, Z., Shishan, J.: US20070048252 (2007).
31. Yoshino, K., Nozawa, S., Isozaki, M., Sawada, S., Kato, I., Matsuzaki, T.: EP1752150A1 (2007).
32. Ruiz-Taylor L-A. Derivatized poly(L-lysine)-graft-poly(ethylene glycol) monolayers as new biomolecular recognition interfaces on metal oxides 219th ACS Natl. Meeting San Francisco, CA, USA March 26-30, 2000, COLL-396 (2000).
33. Walsh MK, Walsh MK, Xinwen W, Bart CW. Optimizing the immobilization of single-stranded DNA onto glass beads. J Biochem Biophys Methods 2001; 47: 221-231.
34. Csucs G, Michel R, Lussi JW, Textor M, Danuser G. Microcontact printing of novel co-polymers in combination with proteins for cell-biological applications. Biomaterials 2003; 24: 1713-1720.
35. Liu VA, Bhatia SN. Three-dimensional photopatterning of hydrogels containing living cells. Biomedical Microdevices 2002; 4: 257-266.
36. Rangelov S, Edwards K, Almgren M, Karlsson G. Steric stabilization of egg-phosphatdylcholine liposomes by copolymers bearing short blocks of lipid-mimetic units. Langmuir 2003; 19: 172-181.
37. Hodenius M, De Cuyper M, Desender L, Müller-Schulte D, Steigel A, Lueken H. Biotinylated Stealth® magnetoliposomes. Chem Phys Lipids 2002; 120: 75-85.
38. Jiang, B. Synthesis and characterization of PEG-modified polymer magnetic microspheres, Guocheng Gongcheng Xuebao 2001; 1 (4): 382-386.
39. Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe M-J, Couvreur P, Vassal G. Poly(ethylene glycol)-coated hexade-cylcyanoacrylate nanospheres display a combined effect for brain tumour targeting. J Pharmacol Exp Therapeutics 2002; 303: 928-936.
40. Harrington KJ, Mubashar M, Peters AM. Polyethylene glycol in the design of tumour-targeting radiolabelled macromolecules-lessons from liposomes and monoclonal antibodies. Quarterly J. of Nuclear Medicine 2002; 46: 171-180.
41. Cahouet A, Denizot B, Hindré F, et al. Biodistribution of dual radiolabeled lipidic nanocapsules in the rat using scintigraphy and gamma counting. Int J Pharmaceutics 2002; 242: 367-371.
42. Benns JM, Kim SW. Tailoring new gene delivery designs for specific targets. J Drug Targeting 2000; 8: 1-12.
43. Zhou W, Yuan X, Wilson A, et al. Efficient intracellular delivery of oligonucleotides formulate in folate receptor-targeted lipid vesicles. Bioconjugate Chem 2002; 13: 1220-1225.
44. Le Bon B, Van Craynest N, Boussif O, Vierling P. Polycationic diblock and random polyethylene glycol- or tris(hydroxymethyl) methyl-grafted (co) telomers for gene transfer: synthesis and evaluation of their in vitro transfection efficiency. Bioconjugate Chem 2002; 13: 1292-1301.
45. Armstrong TKC, Girouard LG, Anchordoquy TJ. Effects of PEGylation on the preservation of cationic lipid/DNA during freeze-thawing and lyophilisation. J Pharm Sci 2002; 91: 2549-2558.
46. Qiu B, Stefanos S, Ma J, et al. A hydrogel prepared by in situ cross-linking of a thiol-containing poly(ethylene glycol)-based copolymer: a new biomaterial for protein drug delivery. Biomaterials 2003; 24: 11-18.
47. Griffith, M., Li, F., Liu, W., Rafat, M.: WO07028258A2 (2007).
48. Bonora, G.M., Campaner, P., Drioli, S.: WO 05123139A1 (2005).
49. Breitenkamp, K., Sill, K., Skaff, H.: US2006047419A2/US20060142506A1 (2006).
50. Hahan, SK.: US20070184015A1 (2007).
51. Rosen, P., Nho, K.: US20070141021A1 (2007).
52. Bentley, M., Zhao, X.: EP1259262B1 (2007).
53. Garreta I., J.M., Yoncheva, K.P.: WO05104648 (2005).
54. Ge, Z., Dorn, H.C., Phillips, J.: WO05097807A2 (2005).
55. 3+ ions for photodynamic therapy. J Controll Release 2007; 117: 104-110.